| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | AGM; PSF; TAF; FSTL2; IBP-7; MAC25; IGFBP-7; RAMSVPS; IGFBP-7v; IGFBPRP1 |
| Entrez GeneID | 3490 |
| clone | 1D9E7 |
| WB Predicted band size | 29.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IGFBP7 (AA: 52-156) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"IGFBP7 as a potential biomarker in hepatocellular carcinoma"** - 作者：Li, Y. et al.
摘要：该研究通过免疫组化(IHC)和Western blot分析，证实IGFBP7抗体在肝细胞癌组织中高表达，且与患者预后不良相关，提示其作为诊断标志物的潜力。
2. **"Role of IGFBP7 in cardiac fibrosis and its detection via specific antibodies"** - 作者：Smith, J.R. et al.
摘要：研究利用IGFBP7抗体在小鼠模型中验证其在心脏纤维化中的作用，发现其通过调节TGF-β信号通路促进纤维化，抗体检测结果支持其作为治疗靶点的可能性。
3. **"Development and validation of a novel IGFBP7 monoclonal antibody for cancer research"** - 作者：Wang, H. et al.
摘要：文章报道了一种高特异性IGFBP7单克隆抗体的开发，通过ELISA和免疫荧光验证其在结直肠癌细胞系中的灵敏度，为肿瘤微环境研究提供新工具。
4. **"IGFBP7 expression in aging and age-related diseases"** - 作者：Kim, S. et al.
摘要：研究通过免疫印迹和免疫组织化学，使用IGFBP7抗体分析其在衰老组织中的表达上调，并探讨其与炎症和细胞衰老的分子机制关联。
注：以上文献为示例，实际引用需根据具体论文内容调整。建议通过PubMed或Google Scholar以“IGFBP7 antibody”及关键词(如biomarker, cancer, fibrosis等)检索最新研究。
IGFBP7 (Insulin-like Growth Factor Binding Protein 7) is a secreted protein belonging to the IGFBP family, though it shares limited homology with other members. It regulates insulin-like growth factor (IGF) signaling by binding IGFs with lower affinity than other IGFBPs, modulating cell proliferation, differentiation, and apoptosis. IGFBP7 also interacts with non-IGF pathways, including TGF-β and Wnt, influencing angiogenesis, fibrosis, and tumor suppression. Its dysregulation is linked to cancers, metabolic disorders, and cardiovascular diseases.
IGFBP7 antibodies are essential tools for detecting and quantifying IGFBP7 in research and diagnostics. They enable the study of its expression patterns, localization, and interactions via techniques like Western blotting, immunohistochemistry (IHC), and ELISA. Commercially available antibodies target specific epitopes, often within its N-terminal domain. In cancer research, these antibodies help evaluate IGFBP7's dual role as a tumor suppressor or promoter, depending on context. Clinically, IGFBP7 is explored as a biomarker for conditions like heart failure and diabetic nephropathy. Validation of antibody specificity remains critical due to structural similarities within the IGFBP superfamily.
×
